The role of airway secretions in COPD - Clinical applications

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 2, Issue 3, 2005, Pages 377-390

  Henke, Markus O ^a   Shah, Samir A ^b   Rubin, Bruce K ^b  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Cough; Expectorants; Mucociliary clearance; Mucokinetic medications; Mucolytics; Physical therapy; Surfactant

Indexed keywords

ACETYLCYSTEINE; AMBROXOL; ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BIOLOGICAL MARKER; BROMHEXINE; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLARITHROMYCIN; DNA; ERYTHROMYCIN; EXPECTORANT AGENT; GUAIFENESIN; INDOMETACIN; IODINATED GLYCEROL; IPRATROPIUM BROMIDE; MACROLIDE; MUCIN; MUCOLYTIC AGENT; OXITROPIUM BROMIDE; ROXITHROMYCIN; SALBUTAMOL; STEROID; SURFACTANT; TIOTROPIUM BROMIDE; XANTHINE;

AIRFLOW; BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DEVICE; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DISEASE EXACERBATION; FOOD AND DRUG ADMINISTRATION; GEL; HUMAN; HYDRATION; INTERVENTION STUDY; LUNG CLEARANCE; MUCUS; PEAK EXPIRATORY FLOW; PHYSIOTHERAPY; PRIORITY JOURNAL; REGISTER; REVIEW; SMOKING; SPUTUM;

EXPECTORANTS; HUMANS; MUCINS; MUCUS; PHYSICAL THERAPY MODALITIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY SURFACTANTS; SPUTUM;

EID: 33646503754     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.1080/15412550500218148     Document Type: Review

References (209)

1. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease NHLBI/WHO Workshop Report. Rev. ed. 2003, 〈http://www.goldcopd.com〉. Global Initiative for Chronic Obstructive Lung Disease (GOLD) Accession: 8/3/04.
2. Lamb D, Reid L. Goblet cell increase in rat bronchial epithelium after exposure to cigarette and cigar tobacco smoke. Br Med J 1969; 1(635):33-35.
3. Rubin BK, King M. Mucus physiology and pathophysiology: therapeutic aspects. In: Derenne JP, Similowski T, Whitelaw WA, eds. Chronic Obstructive Lung Disease. New York: Marcel Dekker, 1996:391-411.
4. Aikawa T, Shimura S, Sasaki H, Takishima T, Yaegashi H, Takahashi T. Morphometric analysis of intraluminal mucus in airways in chronic obstructive pulmonary disease. Am Rev Respir Dis 1989; 140(2):477-482.
5. Vastag E, Matthys H, Zsamboki G, Kohler D, Daikeler G. Mucociliary clearance in smokers. Eur J Respir Dis 1986; 68(2):107-113.
6. Bridges RB, Wyatt RJ, Rehm SR. Effects of smoking on inflammatory mediators and their relationship to pulmonary dysfunction. Eur J Respir Dis, Suppl 1986; 146:145-152.
7. Dalhamn T. In vivo and in vitro ciliotoxic effects of tobacco smoke. Arch Environ Health 1970; 21(5):633-634.
8. King M, Rubin BK. Rheology of airway mucus: relationship with clearance function. In: Takishima T, Shimura S, eds. Airway Secretion: Physiological Bases for the Control of Mucous Hypersecretion. New York: Marcel Dekker, 1994:283-314.
9. Rubin BK, King M. The physiologic effects of smoking in COPD. J Respir Dis 1993; 14:19-25.
10. Zayas JG, Rubin BK, Ramirez O, York E, Lien D, King M. Bronchial mucus rheology and clearability in lung cancer. J Natl Inst Respir Dis 1993; 6:12-20.
11. Jamal K, Cooney TP, Fleetham JA, Thurlbeck WM. Chronic bronchitis. Correlation of morphologic findings to sputum production and flow rates. Am Rev Respir Dis 1984; 129(5):719-722.
12. Lange P, Nyboe J, Appleyard M, Jensen G, Schnohr P. Relation of ventilatory impairment and of chronic mucus hypersecretion to mortality from obstructive lung disease and from all causes. Thorax 1990; 45(8):579-585.
13. In: Rubin BK, Tamaoki J, eds. Antibiotics as Anti-Inflammatory and Immunomodulatory Agents. Basel, Switzerland: Birkhaeuser Verlag, 2004.
14. King M, El Azab J, Phillips DM, Angus GE. Antigen challenge and canine tracheal mucus. Int Arch Allergy Appl Immunol 1985; 77(3):337-342.
15. Rubin BK, Ramirez O, Zayas JG, Finegan B, King M. Respiratory mucus from asymptomatic smokers is better hydrated and more easily cleared by mucociliary action. Am Rev Respir Dis 1992; 145(3):545-547.
16. Dirksen H, Hermansen F, Groth S, Molgaard F. Mucociliary clearance in early simple chronic bronchitis. Eur J Respir Dis, Suppl 1987; 153:145-149.
17. Matthys H, Vastag E, Kohler D, Daikeler G, Fischer J. Mucociliary clearance in patients with chronic bronchitis and bronchial carcinoma. Respiration 1983; 44(5):329-337.
18. Drost EM, Skwarski KM, Sauleda J, Soler N, Roca J, Agusti A, MacNee W. Oxidative stress and airway inflammation in severe exacerbations of COPD. Thorax 2005; 60(4):293-300.
19. MacNee W. Oxidants/antioxidants and chronic obstructive pulmonary disease: pathogenesis to therapy. Novartis Found Symp 2001; 234:169-185.
20. Lopez-Vidriero MT. Airway mucus; production and composition. Chest 1981; 80(6 suppl):799-804.
21. Puchelle E, Zahm JM, Girard F, Bertrand A, Polu JM, Aug F, Sadoul P. Mucociliary transport in vivo and in vitro. Relations to sputum properties in chronic bronchitis. Eur J Respir Dis 1980; 61(5):254-264.
22. Jeffery PK. Morphology of the airway wall in asthma and in chronic obstructive pulmonary disease. Am Rev Respir Dis 1991; 143(5 Pt 1):1152-1158.
23. Schoonbrood DF, Lutter R, Habets FJ, Roos CM, Jansen HM, Out TA. Analysis of plasma-protein leakage and local secretion in sputum from patients with asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1994; 150(6 Pt 1):1519-1527.
24. Zayas JG, Man GC, King M. Tracheal mucus rheology in patients undergoing diagnostic bronchoscopy. Interrelations with smoking and cancer. Am Rev Respir Dis 1990; 141(5 Pt 1):1107-1113.
25. Boat TF, Cheng PW. Biochemistry of airway mucus secretions. Fed Proc 1980; 39:3067-3074.
26. Kaliner M, Marom Z, Patow C, Shelhamer J. Human respiratory mucus. J Allergy Clin Immunol 1984; 73(3):318-323.
27. Kaliner M, Shelhamer JH, Borson B, Nadel J, Patow C, Marom Z. Human respiratory mucus. Am Rev Respir Dis 1986; 134(3):612-621.
28. Thornton DJ, Sheehan JK, Lindgren H, Carlstedt I. Mucus glycoproteins from cystic fibrotic sputum. Macromolecular properties and structural 'architecture'. Biochem J 1991; 276(Pt 3):667-675.
29. Sheehan JK, Richardson PS, Fung DC, Howard M, Thornton DJ. Analysis of respiratory mucus glycoproteins in asthma: a detailed study from a patient who died in status asthmaticus. Am J Respir Cell Mol Biol 1995; 13(6):748-756.
30. Davies JR, Hovenberg HW, Linden CJ, Howard R, Richardson PS, Sheehan JK, Carlstedt I. Mucins in airway secretions from healthy and chronic bronchitic subjects. Biochem J 1996; 313(Pt2):431-439.
31. Reid CJ, Gould S, Harris A. Developmental expression of mucin genes in the human respiratory tract. Am J Respir Cell Mol Biol 1997; 17(5):592-598.
32. Davies JR, Herrmann A, Russell W, Svitacheva N, Wickstrom C, Carlstedt I. Respiratory tract mucins: structure and expression patterns. Novartis Found Symp 2002; 248:76-88.
33. Rose MC, Nickola TJ, Voynow JA. Airway mucus obstruction: mucin glycoproteins, MUC gene regulation and goblet cell hyperplasia. Am J Respir Cell Mol Biol 2001; 25(5):533-537.
34. Kirkham S, Sheehan JK, Knight D, Richardson PS, Thornton DJ. Heterogeneity of airways mucus: variations in the amounts and glycoforms of the major oligomeric mucins MUC5AC and MUC5B. Biochem J 2002; 361(Pt 3):537-546.
35. Wickstrom C, Davies JR, Eriksen GV, Veerman EC, Carlstedt I. MUC5B is a major gel-forming, oligomeric mucin from human salivary gland, respiratory tract and endocervix: identification of glycoforms and C-terminal cleavage. Biochem J 1998; 334(Pt 3):685-693.
36. Thornton DJ, Carlstedt I, Howard M, Devine PL, Price MR, Sheehan JK. Respiratory mucins: identification of core proteins and glycoforms. Biochem J 1996; 316(Pt 3):967-975.
37. Melton L. Does mucus hypersecretion matter in airway disease? Lancet 2002; 359(9321):1924.
38. Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med 1996; 153(5):1530-1535.
39. Aikawa T, Shimura S, Sasaki H, Ebina M, Takishima T. Marked goblet cell hyperplasia with mucus accumulation in the airways of patients who died of severe acute asthma attack. Chest 1992; 101(4):916-921.
40. Welsh MJ, Ramsey BW, Accurso FJ, Cutting GR. Cystic fibrosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill, 2001:5121-5188.
41. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, Pare PD. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350(26): 2645-2653.
42. Takeyama K, Dabbagh K, Lee HM, Agusti C, Lausier JA, Ueki IF, Grattan KM, Nadel JA. Epidermal growth factor system regulates mucin production in airways. Proc Natl Acad Sci U S A 1999; 96(6): 3081-3086.
43. Prescott E, Lange P, Vestbo J. Chronic mucus hypersecretion in COPD and death from pulmonary infection. Eur Respir J 1995; 8(8):1333-1338.
44. Voelkel NF, Tuder R. COPD: exacerbation. Chest 2000; 117(5 suppl 2):376S-379S.
45. Sheehan JK, Howard M, Richardson PS, Longwill T, Thornton DJ. Physical characterization of a low-charge glycoform of the MUC5B mucin comprising the gel-phase of an asthmatic respiratory mucous plug. Biochem J 1999; 338(Pt 2):507-513.
46. Voynow JA, Selby DM, Rose MC. Mucin gene expression (MUC1, MUC2, and MUC5/5AC) in nasal epithelial cells of cystic fibrosis, allergic rhinitis, and normal individuals. Lung 1998; 176:345-354.
47. Thornton DJ, Davies JR, Kraayenbrink M, Richardson PS, Sheehan JK, Carlstedt I. Mucus glycoproteins from 'normal' human tracheobronchial secretion. Biochem J 1990; 265(1):179-186.
48. Hovenberg HW, Davies JR, Carlstedt I. Different mucins are produced by the surface epithelium and the submucosa in human trachea: identification of MUC5AC as a major mucin from the goblet cells. Biochem J 1996; 318(Pt 1):319-324.
49. Sheehan JK, Hanski C, Corfield AP, Paraskeva C, Thornton DJ. Mucin biosynthesis and macromolecular assembly. Biochem Soc Trans 1995; 23(4):819-821.
50. Sheehan JK, Kirkham S, Howard M, Woodman P, Kutay S, Brazeau C, Buckley J, Thornton DJ. Identification of molecular intermediates in the assembly pathway of the MUC5AC mucin. J Biol Chem 2004; 279(15):15698-15705.
51. Innés AL, Dolganov GM, Woodruff PG, Cadbury P, Carter R, Ferrando R, Lazarus SC, Fahy JV. Characterizing epithelial mucin stores and mucin gene expression in COPD. Am J Respir Crit Care Med 2004; 169(7):A712.
52. Caramori G, Di Gregorio C, Carlstedt I, Casolari P, Guzzinati I, Adcock IM, Barnes PJ, Ciaccia A, Cavallesco G, Chung KF, Papi A. Mucin expression in peripheral airways of patients with chronic obstructive pulmonary disease. Histopathology 2004; 45(5):477-484.
53. Albers GM, Tomkiewicz RP, May MK, Ramirez OE, Rubin BK. Ring distraction technique for measuring surface tension of sputum: relationship to sputum clearability. J Appl Physiol 1996; 81(6):2690-2695.
54. Rubin BK. Surface properties of respiratory secretions: relationship to mucus transport. In: Baum G, Priel Z, Roth Y, Liron N, Ostfield E, eds. Cilia, Mucus, and Mucociliary Interactions. New York: Marcel Dekker, 1998:317-323.
55. Picot R, Das I, Reid L. Pus, deoxyribonucleic acid, and sputum viscosity. Thorax 1978; 33(2):235-242.
56. Verdugo P, Tam PY, Butler J. Conformational structure of respiratory mucus studied by laser correlation spectroscopy. Biorheology 1983; 20(2):223-230.
57. Sheils CA, Kas J, Travassos W, Allen PG, Janmey PA, Wohl ME, Stossel TP. Actin filaments mediate DNA fiber formation in chronic inflammatory airway disease. Am J Pathol 1996; 148(3):919-927.
58. Tomkiewicz RP, Kishioka C, Freemann J, Rubin BK. DNA and actin filaments ultrastructure in cystic fibrosis sputum. In: Baum GL, Priel Z, Roth Y, Liron N, Ostfield E, eds. Cilia, Mucus, and Mucociliary Interactions. New York: Marcel Dekker, 1998:333-341.
59. Ferry JD. Viscoelastic Properties of Polymers. 3rd ed. New York: Wiley, 1980.
60. Shak S, Capon DJ, Hellmiss R, Marsters SA, Baker CL. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. PNAS 1990; 87(23):9188-9192.
61. Shah PL, Conway S, Scott SF, Rainisio M, Wildman M, Stableforth D, Hodson ME. A case-controlled study with dornase alfa to evaluate impact on disease progression over a 4-year period. Respiration 2001; 68(2): 160-164.
62. Shah PL, Scott SF, Knight RA, Marriott C, Ranasinha C, Hodson ME. In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis. Thorax 1996; 51(2):119-125.
63. Zahm JM, Galabert C, Chaffin A, Chazalette JP, Grosskopf C, Puchelle E. Improvement of cystic fibrosis airway mucus transportability by recombinant human DNase is related to changes in phospholipid profile. Am J Respir Crit Care Med 1998; 157(6 Pt 1): 1779-1784.
64. Fick RB, Anzueto A, Mahutte K. Recombinant DNase mortality reduction in acute exacerbations of chronic bronchitis. Clin Res 1994; 42(2):A294.
65. Bone RC, Fuchs H, Fox NL. The chronic obstructive pulmonary disease mortality endpoint trial. Chest 1995; 108(3 suppl):R.
66. Wills PJ, Wodehouse T, Corkery K, Mallon K, Wilson R, Cole PJ. Short-term recombinant human DNase in bronchiectasis. Effect on clinical state and in vitro sputum transportability. Am J Respir Crit Care Med 1996; 154(2 Pt 1):413-417.
67. Jager EG. Double-blind, placebo-controlled clinical evaluation of guaimesal in outpatients. Clin Ther 1989; 11(3):341-362.
68. Thomson ML, Pavia D, McNicol MW. A preliminary study of the effect of guaiphenesin on mucociliary clearance from the human lung. Thorax 1973; 28(6):742-747.
69. Shim C, King M, Williams MH Jr. Lack of effect of hydration on sputum production in chronic bronchitis. Chest 1987; 92(4):679-682.
70. Pavia D, Agnew JE, Glassman JM, Sutton PP, Lopez-Vidriero MT, Soyka JP, Clarke SW. Effects of iodopropylidene glycerol on tracheobronchial clearance in stable, chronic bronchitic patients. Eur J Respir Dis 1985; 67(3): 177-184.
71. Petty TL. The National Mucolytic Study. Results of a randomized, double-blind, placebo-controlled study of iodinated glycerol in chronic obstructive bronchitis. Chest 1990; 97(1):75-83.
72. Rubin BK, Ramirez O, Ohar JA. Iodinated glycerol has no effect on pulmonary function, symptom score, or sputum properties in patients with stable chronic bronchitis. Chest 1996; 109(2):348-352.
73. Pavia D, Thomson ML, Clarke SW. Enhanced clearance of secretions from the human lung after the administration of hypertonic saline aerosol. Am Rev Respir Dis 1978; 117(2):199-203.
74. Rutgers SR, Timens W, Kaufmann HF, van der Mark TW, Koeter GH, Postma DS. Comparison of induced sputum with bronchial wash, bronchoalveolar lavage and bronchial biopsies in COPD. Eur Respir J 2000; 15(1):109-115.
75. Eng PA, Morton J, Douglass JA, Riedler J, Wilson J, Robertson CF. Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatr Pulmonol 1996; 21(2):77-83.
76. Poole PJ, Brodie SM, Stewart JM, Black PN. The effects of nebulised isotonic saline and terbutaline on breathlessness in severe chronic obstructive pulmonary disease (COPD). Aust N Z J Med 1998; 28(3):322-326.
77. Smith JJ, Travis SM, Greenberg EP, Welsh MJ. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid [published erratum appears in Cell 1996 Oct. 18;87(2):following 355]. Cell 1996; 85:229-236.
78. Taube C, Holz O, Mucke M, Jorres RA, Magnussen H. Airway response to inhaled hypertonic saline in patients with moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164(10 Pt 1): 1810-1815.
79. King M, Dasgupta B, Tomkiewicz RP, Brown NE. Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I. Am J Respir Crit Care Med 1997; 156(1):173-177.
80. Zuhlke IE, Kanniess F, Richter K, Nielsen-Gode D, Bohme S, Jorres RA, Magnussen H. Montelukast attenuates the airway response to hypertonic saline in moderate-to-severe COPD. Eur Respir J 2003; 22(6):926-930.
81. Sheffner AL, Medler EM, Jacobs LW, Sarett HP. The in vitro reduction in viscosity of human tracheobronchial secretions by acetylcysteine. Am Rev Respir Dis 1964; 90:721-729.
82. Rhee CS, Majima Y, Cho JS, Arima S, Min YG, Sakakura Y. Effects of mucokinetic drugs on rheological properties of reconstituted human nasal mucus. Arch Otolaryngol Head Neck Surg 1999; 125(1): 101-105.
83. Boman G, Backer U, Larsson S, Melander B, Wahlander L. Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: report of a trial organized by the Swedish Society for Pulmonary Diseases. Eur J Respir Dis 1983; 64(6):405-415.
84. Brocard H, Charpin J, Germouty J. Multicenter, double-blind study of oral acetylcysteine vs. placebo. Eur J Respir Dis, Suppl 1980; 111:65-69.
85. Dorow P, Weiss T, Felix R, Kohler M. Influence of tasuldine and acetylcysteine on mucociliary clearance in patients with chronic airways obstruction. Arzneim-Forsch 1986; 36(1):131-133.
86. Dueholm M, Nielsen C, Thorshauge H, Evald T, Hansen NC, Madsen HD, Maltbaek N. N-acetylcysteine by metered dose inhaler in the treatment of chronic bronchitis: a multi-centre study. Respir Med 1992; 86(2):89-92.
87. Grassi C, Morandini GC. A controlled trial of intermittent oral acetylcysteine in the long-term treatment of chronic bronchitis. Eur J Clin Pharmacol 1976; 09(5-6):393-396.
88. Hansen NC, Skriver A, Brorsen-Riis L, Balslov S, Evald T, Maltbaek N, Gunnersen G, Garsdal P, Sander P, Pedersen JZ. Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis. Respir Med 1994; 88(7):531-535.
89. Oral N-acetylcysteine and exacerbation rates in patients with chronic bronchitis and severe airways obstruction. British Thoracic Society Research Committee. Thorax 1985; 40(11):832-835.
90. Tattersall AB, Bridgman KM, Huitson A. Irish general practice study of acetylcysteine (Fabrol) in chronic bronchitis. J Int Med Res 1984; 12(2):96-101.
91. Gerrits CM, Herings RM, Leufkens HG, Lammers JW. N-acetylcysteine reduces the risk of re-hospitalisation among patients with chronic obstructive pulmonary disease. Eur Respir J 2003; 21(5):795-798.
92. Black PN, Morgan-Day A, McMillan TE, Poole PJ, Young RP. Randomised, controlled trial of N-acetylcysteine for treatment of acute exacerbations of chronic obstructive pulmonary disease. BMC Pulm Med 2004; 4(1):13.
93. Christensen F, Kjer J, Ryskjaer S, Arseth-Hansen P. Bromhexine in chronic bronchitis. Br Med J 1970; 4(727):117.
94. Clarke SW, Lopez-Vidriero MT, Pavia D, Thomson ML. The effect of sodium 2-mercapto-ethane sulphonate and hypertonic saline aerosols on bronchial clearance in chronic bronchitis. Br J Clin Pharmacol 1979; 7(1):39-44.
95. Pavia D, Sutton PP, Lopez-Vidriero MT, Agnew JE, Clarke SW. Drug effects on mucociliary function. Eur J Respir Dis, Suppl 1983; 128(Pt 1):304-317.
96. Gent M, Knowlson PA, Rime FJ. Effect of bromhexine on ventilatory capacity in patients with a variety of chest diseases. Lancet 1969; 2(7630):1094-1096.
97. Braga PC, Allegra L, Rampoldi C, Ornaghi A, Beghi G. Long-lasting effects on rheology and clearance of bronchial mucus after short-term administration of high doses of carbocysteine-lysine to patients with chronic bronchitis. Respiration 1990; 57(6):353-358.
98. Castiglioni CL, Gramolini C. Effect of long-term treatment with sobrerol on the exacerbations of chronic bronchitis. Respiration 1986; 50(3):202-217.
99. Goodman RM, Yergin BM, Sackner MA. Effects of S-carboxymethylcysteine on tracheal mucus velocity. Chest 1978; 74(6):615-618.
100. Sueyoshi S, Miyata Y, Masumoto Y, Ishibashi Y, Matsuzawa S, Harano N, Tsuru K, Imai S. Reduced airway inflammation and remodeling in parallel with mucin 5AC protein expression decreased by s-carboxymethylcysteine, a mucoregulant, in the airways of rats exposed to sulfur dioxide. Int Arch Allergy Immunol 2004; 134(4):273-280.
101. Schreiber J, Bohnsteen B, Rosahl W. Influence of mucolytic therapy on respiratory mechanics in patients with chronic obstructive pulmonary disease. Eur J Med Res 2002; 7(3):98-102.
102. Tekeres M, Horvath A, Bardosi L, Kenyeres P. Clinical studies on the mucolytic effect of mesna. Clin Ther 1981; 4(1):56-60.
103. Ramsey BW, Astley SJ, Aitken ML, Burke W, Colin AA, Dorkin HL, Eisenberg JD, Gibson RL, Harwood IR, Schidlow DV. Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. Am Rev Respir Dis 1993; 148(1):145-151.
104. Hubbard RC, McElvaney NG, Birrer P, Shak S, Robinson WW, Jolley C, Wu M, Chernick MS, Crystal RG. A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis. N Engl J Med 1992; 326(12):812-815.
105. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, Rosenstein BJ, Smith AL, Wohl ME. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group [see comments]. N Engl J Med 1994; 331:637-642.
106. Paul K, Rietschel E, Ballmann M, Griese M, Worlitzsch D, Shute J, Chen C, Schink T, Doring G, van Koningsbruggen S, Wahn U, Ratjen F, Bronchoalveolar Lavage for the Evaluation of Antiinflammatory Treatment Study Group. Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis. Am J Respir Crit Care Med 2004; 169(6):719-725.
107. Puchelle E, Zahm JM, de Bentzmann S, Grosskopf C, Shak S, Mougel D, Polu JM. Effects of rhDNase on purulent airway secretions in chronic bronchitis. Eur Respir J 1996; 9(4):765-769.
108. Vasconcellos CA, Allen PG, Wohl ME, Drazen JM, Janmey PA, Stossel TP. Reduction in viscosity of cystic fibrosis sputum in vitro by gelsolin. Science 1994; 263(5149):969-971.
109. Fuloria M, Rubin BK. Evaluating the efficacy of mucoactive aerosol therapy. Respir Care 2000; 45(7):868-873.
110. Mossberg B, Strandberg K, Philipson K, Camner P. Tracheobronchial clearance in bronchial asthma: response to beta-adrenoceptor stimulation. Scand J Respir Dis 1976; 57(3): 119-128.
111. Isawa T, Teshima T, Hirano T, Ebina A, Konno K. Effect of oral salbutamol on mucociliary clearance mechanisms in the lungs. Tohoku J Exp Med 1986; 150(1):51-61.
112. Pavia D, Bateman JR, Sheahan NF, Clarke SW. Clearance of lung secretions in patients with chronic bronchitis: effect of terbutaline and ipratropium bromide aerosols. Eur J Respir Dis 1980; 61(5):245-253.
113. Mortensen J, Groth S, Lange P, Hermansen F. Effect of terbutaline on mucociliary clearance in asthmatic and healthy subjects after inhalation from a pressurised inhaler and a dry powder inhaler. Thorax 1991; 46(11):817-823.
114. Wanner A. Effects of methylxanthines on airway mucociliary function. Am J Med 1985; 79(6A):16-21.
115. Finley TN, Ladman AJ. Low yield of pulmonary surfactant in cigarette smokers. N Engl J Med 1972; 286(5):223-227.
116. Higenbottam T. Pulmonary surfactant and chronic lung disease. Eur J Respir Dis, Suppl 1987; 153:222-228.
117. Girod S, Galabert C, Lecuire A, Zahm JM, Puchelle E. Phospholipid composition and surface-active properties of tracheobronchial secretions from patients with cystic fibrosis and chronic obstructive pulmonary diseases. Pediatr Pulmonol 1992; 13(1):22-27.
118. Rubin BK. Therapeutic aerosols and airway secretions. J Aerosol Med 1996; 9(1):123-130.
119. Anzueto A, Jubran A, Ohar JA, Piquette CA, Rennard SI, Colice G, Pattishall EN, Barrett J, Engle M, Perret KA, Rubin BK. Effects of aerosolized surfactant in patients with stable chronic bronchitis: a prospective randomized controlled trial. JAMA 1997; 278(17):1426-1431.
120. Yanaura S, Takeda H, Nishimura T, Misawa M. Histological and histochemical changes of tracheal secretory cells following bromhexine treatment (author's transl). Nippon Yakurigaku Zasshi 1981; 77(6):559-568.
121. Ziment I. Mucokinetic Agents. Respiratory Pharmacology and Therapeutics. Philadelphia: W.B. Saunders Company, 1976:60-104.
122. Valenti S, Marenco G. Italian multicenter study on the treatment of chronic obstructive lung disease with bromhexine. A double-blind placebo-controlled trial. Respiration 1989; 56(1-2): 11-15.
123. Germouty J, Jirou-Najou JL. Clinical efficacy of ambroxol in the treatment of bronchial stasis. Clinical trial in 120 patients at two different doses. Respiration 1987; 51 suppl 1:37-41.
124. Ericsson CH, Juhasz J, Mossberg B, Philipson K, Svartengren M, Camner P. Influence of ambroxol on tracheobronchial clearance in simple chronic bronchitis. Eur J Respir Dis 1987; 70(3):163-170.
125. Olivieri D, Zavattini G, Tomasini G, Daniotti S, Bonsignore G, Ferrara G, Carnimeo N, Chianese R, Catena E, Marcatili S. Ambroxol for the prevention of chronic bronchitis exacerbations: long-term multicenter trial. Protective effect of ambroxol against winter semester exacerbations: a double-blind study versus placebo. Respiration 1987; 51 suppl 1:42-51.
126. Prevention of chronic bronchitis exacerbations with ambroxol (mucosolvan retard). An open, long-term, multicenter study in 5,635 patients. Respiration 1989; 55 suppl 1:84-96.
127. Guyatt GH, Townsend M, Kazim F, Newhouse MT. A controlled trial of ambroxol in chronic bronchitis. Chest 1987; 92(4):618-620.
128. Rogers DF. Pharmacological regulation of the neuronal control of airway mucus secretion. Curr Opin Pharmacol 2002; 2(3):249-255.
129. Ramnarine SI, Haddad EB, Khawaja AM, Mak JC, Rogers DF. On muscarinic control of neurogenic mucus secretion in ferret trachea. J Physiol 1996; 494(Pt 2):577-586.
130. Nakaya M, Yuasa T, Usui N. Immunohistochemical localization of subtypes of muscarinic receptors in human inferior turbinate mucosa. Ann Otol Rhinol Laryngol 2002; 111(7 Pt 1):593-597.
131. Hybbinette JC, Mercke U. Effects of sympathomimetic agonists and antagonists on mucociliary activity. Acta Oto-Laryngol 1982; 94(1-2):121-130.
132. Francis RA, Thompson ML, Pavia D, Douglas RB. Ipratropium bromide: mucociliary clearance rate and airway resistance in normal subjects. Br J Dis Chest 1977; 71(3):173-178.
133. Matthys H, Hundenborn J, Daikeler G, Kohler D. Influence of 0.2 mg ipratropium bromide on mucociliary clearance in patients with chronic bronchitis. Respiration 1985; 48(4):329-339.
134. Lopez-Vidriero MT, Costello J, Clark TJ, Das I, Keal EE, Reid L. Effect of atropine on sputum production. Thorax 1975; 30(5):543-547.
135. Giordano A, Holsclaw D, Litt M. Effects of various drugs on canine tracheal mucociliary transport. Ann Otol Rhinol Laryngol 1978; 87(4 Pt 1):484-490.
136. King M, Angus GE. Effect of aerosolized bronchodilators on viscoelastic properties of canine tracheal mucus. Chest 1981; 80(6 suppl):852-854.
137. Kishioka C, Cheng PW, Seftor RE, Lartey PA, Rubin BK. Regulation of mucin secretion in the ferret trachea. Otolaryngol Head Neck Surg 1997; 117(5):480-486.
138. Tamaoki J, Chiyotani A, Tagaya E, Sakai N, Konno K. Effect of long term treatment with oxitropium bromide on airway secretion in chronic bronchitis and diffuse panbronchiolitis. Thorax 1994; 49(6):545-548.
139. Ghafouri MA, Patil KD, Kass I. Sputum changes associated with the use of ipratropium bromide. Chest 1984; 86(3):387-393.
140. Hvizdos KM, Goa KL. Tiotropium bromide. Drugs 2002; 62(8): 1195-1203.
141. Davis B, Roberts AM, Coleridge HM, Coleridge JC. Reflex tracheal gland secretion evoked by stimulation of bronchial C-fibers in dogs. J Appl Physiol 1982; 53(4):985-991.
142. Coles SJ, Neill KH, Reid LM. Potent stimulation of glycoprotein secretion in canine trachea by substance P. J Appl Physiol 1984; 57(5):1323-1327.
143. De Sanctis GT, Rubin BK, Ramirez O, King M. Ferret tracheal mucus rheology, clearability and volume following administration of substance P or methacholine. Eur Respir J 1993; 6(1):76-82.
144. Jeffery PK. Anti-inflammatory drugs and experimental bronchitis. Eur J Respir Dis, Suppl 1986; 146:245-257.
145. Marom Z, Shelhamer J, Ailing D, Kaliner M. The effects of corticosteroids on mucous glycoprotein secretion from human airways in vitro. Am Rev Respir Dis 1984; 129(1):62-65.
146. Tamaoki J, Chiyotani A, Kobayashi K, Sakai N, Kanemura T, Takizawa T. Effect of indomethacin on bronchorrhea in patients with chronic bronchitis, diffuse panbronchiolitis, or bronchiectasis. Am Rev Respir Dis 1992; 145(3):548-552.
147. Goswami SK, Kivity S, Marom Z. Erythromycin inhibits respiratory glycoconjugate secretion from human airways in vitro. Am Rev Respir Dis 1990; 141(1):72-78.
148. Tamaoki J, Takeyama K, Tagaya E, Konno K. Effect of clarithromycin on sputum production and its rheological properties in chronic respiratory tract infections. Antimicrob Agents Chemother 1995; 39(8): 1688-1690.
149. Rubin BK, Druce H, Ramirez OE, Palmer R. Effect of clarithromycin on nasal mucus properties in healthy subjects and in patients with purulent rhinitis. Am J Respir Crit Care Med 1997; 155(6):2018-2023.
150. Koh YY, Lee MH, Sun YH, Sung KW, Chae JH. Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double-blind, placebo-controlled study [see comments]. Eur Respir J 1997; 10(5):994-999.
151. Tamaoki J, Takeyama K, Yamawaki I, Kondo M, Konno K. Lipopolysaccharide- induced goblet cell hypersecretion in the guinea pig trachea: inhibition by macrolides. Am J Physiol 1997; 272(1 Pt 1):L15-L19.
152. Rubin BK, Henke MO, Dalhoff A. Anti-inflammatory properties of antibiotics other than macrolides. In: Rubin BK, Tamaoki J, eds. Antibiotics as Anti-Inflammatory and Immunomodulatory Agents. Basel, Switzerland: Birkhaeuser Verlag, 2004:247-267.
153. Campbell AH, O'Connell JM, Wilson F. The effect of chest physiotherapy upon the FEV1 in chronic bronchitis. Med J Aust 1975; 1(2):33-35.
154. May DB, Munt PW. Physiologic effects of chest percussion and postural drainage in patients with stable chronic bronchitis. Chest 1979; 75(1):29-32.
155. Oldenburg FA Jr, Dolovich MB, Montgomery JM, Newhouse MT. Effects of postural drainage, exercise, and cough on mucus clearance in chronic bronchitis. Am Rev Respir Dis 1979; 120(4):739-745.
156. Wollmer P, Ursing K, Midgren B, Eriksson L. Inefficiency of chest percussion in the physical therapy of chronic bronchitis. Eur J Respir Dis 1985; 66(4):233-239.
157. van der Schans CP. Airway clearance: assessment of techniques. Paediatr Respir Rev 2002; 3(2):110-114.
158. Main E, Prasad A, van der Schans CP. Conventional chest physiotherapy compared to other airway clearance techniques for cystic fibrosis. Cochrane Database Syst Rev 2005, DOI: 10.1002/14651858.CD002011.pub2.(1).
159. van der Schans CP, Postma DS, Koeter GH, Rubin BK. Physiotherapy and bronchial mucus transport. Eur Respir J 1999; 13(6):1477-1486.
160. Kim CS, Rodriguez CR, Eldridge MA, Sackner MA. Criteria for mucus transport in the airways by two-phase gas-liquid flow mechanism. J Appl Physiol 1986; 60(3):901-907.
161. Bennett WD, Foster WM, Chapman WF. Cough-enhanced mucus clearance in the normal lung. J Appl Physiol 1990; 69(5):1670-1675.
162. van der Schans CP, Piers DA, Postma DS. Effect of manual percussion on tracheobronchial clearance in patients with chronic airflow obstruction and excessive tracheobronchial secretion. Thorax 1986; 41(6):448-452.
163. van Hengstum M, Festen J, Beurskens C, Hankel M, Beekman F, Corstens F. Conventional physiotherapy and forced expiration manoeuvres have similar effects on tracheobronchial clearance. Eur Respir J 1988; 1(8):758-761.
164. van der Schans CP, Piers DA, Beekhuis H, Koeter GH, van der Mark TW, Postma DS. Effect of forced expirations on mucus clearance in patients with chronic airflow obstruction: effect of lung recoil pressure. Thorax 1990; 45(8):623-627.
165. Wong JW, Keens TG, Wannamaker EM, Crozier DN, Levison H, Aspin N. Effects of gravity on tracheal mucus transport rates in normal subjects and in patients with cystic fibrosis. Pediatrics 1977; 60(2): 146-152.
166. Vandenplas Y, Diericx A, Blecker U, Lanciers S, Deneyer M. Esophageal pH monitoring data during chest physiotherapy. J Pediatr Gastroenterol Nutr 1991; 13(1):23-26.
167. van Hengstum M, Festen J, Beurskens C, Hankel M, van den BW, Corstens F. No effect of oral high frequency oscillation combined with forced expiration manoeuvres on tracheobronchial clearance in chronic bronchitis. Eur Respir J 1990; 3(1): 14-18.
168. Hansen LG, Warwick WJ. High-frequency chest compression system to aid in clearance of mucus from the lung. Biomed Instrum Technol 1990; 24(4):289-294.
169. Warwick WJ, Hansen LG. The long-term effect of high-frequency chest compression therapy on pulmonary complications of cystic fibrosis. Pediatr Pulmonol 1991; 11(3):265-271.
170. Freitag L, Long WM, Kim CS, Wanner A. Removal of excessive bronchial secretions by asymmetric high-frequency oscillations. J Appl Physiol 1989; 67(2):614-619.
171. Sutton PP, Parker RA, Webber BA, Newman SP, Garland N, Lopez-Vidriero MT, Pavia D, Clarke SW. Assessment of the forced expiration technique, postural drainage and directed coughing in chest physiotherapy. Eur J Respir Dis 1983; 64(1):62-68.
172. Lindemann H. The value of physical therapy with VRP 1-Desitin ("Flutter"). Pneumologie 1992; 46(12):626-630.
173. Thompson CS, Harrison S, Ashley J, Day K, Smith DL. Randomised crossover study of the Flutter device and the active cycle of breathing technique in non-cystic fibrosis bronchiectasis. Thorax 2002; 57(5):446-448.
174. Wolkove N, Kamel H, Rotaple M, Baltzan MA Jr. Use of a mucus clearance device enhances the bronchodilator response in patients with stable COPD. Chest 2002; 121(3):702-707.
175. Konstan MW, Stern RC, Doershuk CF. Efficacy of the Flutter device for airway mucus clearance in patients with cystic fibrosis. J Pediatr 1994; 124(5 Pt 1):689-693.
176. Hofmeyr JL, Webber BA, Hodson ME. Evaluation of positive expiratory pressure as an adjunct to chest physiotherapy in the treatment of cystic fibrosis. Thorax 1986; 41(12):951-954.
177. Christensen HR, Simonsen K, Lange P, Clementsen P, Kampmann JP, Viskum K, Heideby J, Koch U. PEEP-masks in patients with severe obstructive pulmonary disease: a negative report. Eur Respir J 1990; 3(3):267-272.
178. Falk M, Kelstrup M, Andersen JB, Kinoshita T, Falk P, Stovring S, Gothgen I. Improving the ketchup bottle method with positive expiratory pressure, PEP, in cystic fibrosis. Eur J Respir Dis 1984; 65(6):423-432.
179. Christensen EF, Nedergaard T, Dahl R. Long-term treatment of chronic bronchitis with positive expiratory pressure mask and chest physiotherapy. Chest 1990; 97(3):645-650.
180. McCoy K, Hamilton S, Johnson C. Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Pulmozyme Study Group. Chest 1996; 110(4):889-895.
181. Peters KD, Kochanek KD, Murphy SL. Deaths: final data for 1996. Natl Vital Stat Rep 1998; 47(9):1-100.
182. Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance - United States, 1971-2000. MMWR, Surveill Summ 2002; 51(6):1-16.
183. Connors AF Jr, Dawson NV, Thomas C, Harrell FE Jr, Desbiens N, Fulkerson WJ, Kussin P, Bellamy P, Goldman L, Knaus WA. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med 1996; 154(4 Pt 1):959-967.
184. Seneff MG, Wagner DP, Wagner RP, Zimmerman JE, Knaus WA. Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. JAMA 1995; 274(23):1852-1857.
185. Fuso L, Incalzi RA, Pistelli R, Muzzolon R, Valente S, Pagliari G, Gliozzi F, Ciappi G. Predicting mortality of patients hospitalized for acutely exacerbated chronic obstructive pulmonary disease. Am J Med 1995; 98(3):272-277.
186. Emerman CL, Effron D, Lukens TW. Spirometric criteria for hospital admission of patients with acute exacerbation of COPD. Chest 1991; 99(3):595-599.
187. Miravitlles M, Guerrero T, Mayordomo C, Sanchez-Agudo L, Nicolau F, Segu JL. Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis. The EOLO Study Group. Respiration 2000; 67(5):495-501.
188. Miravitlles M. Exacerbations of chronic obstructive pulmonary disease: when are bacteria important? Eur Respir J, Suppl 2002; 36:9s-19s.
189. Ball P, Harris JM, Lowson D, Tillotson G, Wilson R. Acute infective exacerbations of chronic bronchitis. QJM 1995; 88(1):61-68.
190. Adams SG, Melo J, Luther M, Anzueto A. Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD. Chest 2000; 117(5):1345-1352.
191. Wilson R, Schentag JJ, Ball P, Mandell L. A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. Clin Ther 2002; 24(4):639-652.
192. Chodosh S, Schreurs A, Siami G, Barkman HW Jr, Anzueto A, Shan M, Moesker H, Stack T, Kowalsky S. Efficacy of oral ciprofloxacin vs. clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. Clin Infect Dis 1998; 27(4):730-738.
193. Chodosh S, McCarty J, Farkas S, Drehobl M, Tosiello R, Shan M, Aneiro L, Kowalsky S. Randomized, double-blind study of ciprofloxacin and cefuroxime axetil for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. Clin Infect Dis 1998; 27(4):722-729.
194. Anzueto A, Rizzo JA, Grossman RF. The infection-free interval: its use in evaluating antimicrobial treatment of acute exacerbation of chronic bronchitis. Clin Infect Dis 1999; 28(6): 1344-1345.
195. White AJ, Gompertz S, Stockley RA. Chronic obstructive pulmonary disease. 6: the aetiology of exacerbations of chronic obstructive pulmonary disease. Thorax 2003; 58(1):73-80.
196. Stockley RA, O'Brien C, Pye A, Hill SL. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 2000; 117(6): 1638-1645.
197. Bhowmik A, Seemungal TA, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000; 55(2):114-120.
198. Wedzicha JA, Seemungal TA, MacCallum PK, Paul EA, Donaldson GC, Bhowmik A, Jeffries DJ, Meade TW. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost 2000; 84(2):210-215.
199. Pratico D, Basili S, Vieri M, Cordova C, Violi F, Fitzgerald GA. Chronic obstructive pulmonary disease is associated with an increase in urinary levels of isoprostane F2alpha-III, an index of oxidant stress. Am J Respir Crit Care Med 1998; 158(6):1709-1714.
200. Dev D, Wallace E, Sankaran R, Cunniffe J, Govan JR, Wathen CG, Emmanuel FX. Value of C-reactive protein measurements in exacerbations of chronic obstructive pulmonary disease. Respir Med 1998; 92(4):664-667.
201. Fiorini G, Crespi S, Rinaldi M, Oberti E, Vigorelli R, Palmieri G. Serum ECP and MPO are increased during exacerbations of chronic bronchitis with airway obstruction. Biomed Pharmacother 2000; 54(5):274-278.
202. Saetta M, Di Stefano DiA, Maestrelli P, Turato G, Ruggieri MP, Roggeri A, Calcagni P, Mapp CE, Ciaccia A, Fabbri LM. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med 1994; 150(6 Pt 1):1646-1652.
203. Zhu J, Qiu YS, Majumdar S, Gamble E, Matin D, Turato G, Fabbri LM, Barnes N, Saetta M, Jeffery PK. Exacerbations of bronchitis: bronchial eosinophilia and gene expression for interleukin-4, interleukin-5, and eosinophil chemoattractants. Am J Respir Crit Care Med 2001; 164(1):109-116.
204. Tzanakis N, Chrysofakis G, Tsoumakidou M, Kyriakou D, Tsiligianni J, Bouros D, Siafakas NM. Induced sputum CD8 T-lymphocyte subpopulations in chronic obstructive pulmonary disease. Respir Med 2004; 98(1):57-65.
205. Selby C, Drost E, Lannan S, Wraith PK, MacNee W. Neutrophil retention in the lungs of patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1991; 143(6):1359-1364.
206. Balbi B, Bason C, Balleari E, Fiasella F, Pesci A, Ghio R, Fabiano F. Increased bronchoalveolar granulocytes and granulocyte/macrophage colony-stimulating factor during exacerbations of chronic bronchitis. Eur Respir J 1997; 10(4):846-850.
207. Bhowmik A, Seemungal TA, Sapsford RJ, Devalia JL, Wedzicha JA. Comparison of spontaneous and induced sputum for investigation of airway inflammation in chronic obstructive pulmonary disease. Thorax 1998; 53(11):953-956.
208. Beeh KM, Beier J, Kornmann O, Mander A, Buhl R. Long-term repeatability of induced sputum cells and inflammatory markers in stable, moderately severe COPD. Chest 2003; 123(3):778-783.
209. Gompertz S, O'Brien C, Bayley DL, Hill SL, Stockley RA. Changes in bronchial inflammation during acute exacerbations of chronic bronchitis. Eur Respir J 2001; 17(6):1112-1119.